A detailed history of Meeder Asset Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Meeder Asset Management Inc holds 182,210 shares of ABBV stock, worth $31.3 Million. This represents 2.43% of its overall portfolio holdings.

Number of Shares
182,210
Previous 112,617 61.8%
Holding current value
$31.3 Million
Previous $19.3 Million 86.28%
% of portfolio
2.43%
Previous 1.36%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$163.84 - $199.33 $11.4 Million - $13.9 Million
69,593 Added 61.8%
182,210 $36 Million
Q2 2024

Aug 08, 2024

BUY
$154.79 - $180.76 $13.3 Million - $15.5 Million
85,928 Added 321.96%
112,617 $19.3 Million
Q1 2024

May 07, 2024

SELL
$159.82 - $182.1 $18.5 Million - $21.1 Million
-115,815 Reduced 81.27%
26,689 $4.86 Million
Q4 2023

Jan 25, 2024

BUY
$137.6 - $154.97 $19.2 Million - $21.6 Million
139,313 Added 4365.81%
142,504 $22.1 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $11.7 Million - $13.6 Million
-87,656 Reduced 96.49%
3,191 $475,000
Q2 2023

Aug 11, 2023

BUY
$132.51 - $164.9 $177,430 - $220,801
1,339 Added 1.5%
90,847 $12.2 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $4.91 Million - $5.65 Million
33,924 Added 61.03%
89,508 $14.3 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $7.67 Million - $9.19 Million
-55,431 Reduced 49.93%
55,584 $8.99 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $34,760 - $39,867
259 Added 0.23%
111,015 $14.9 Million
Q2 2022

Aug 08, 2022

SELL
$137.62 - $174.96 $3.27 Million - $4.16 Million
-23,784 Reduced 17.68%
110,756 $17 Million
Q1 2022

May 10, 2022

BUY
$131.98 - $163.75 $17.8 Million - $22 Million
134,540 New
134,540 $21.8 Million
Q4 2021

Feb 11, 2022

SELL
$107.43 - $135.93 $13.7 Million - $17.3 Million
-127,197 Closed
0 $0
Q3 2021

Nov 08, 2021

SELL
$106.4 - $120.78 $74,905 - $85,029
-704 Reduced 0.55%
127,197 $13.7 Million
Q2 2021

Aug 09, 2021

BUY
$105.21 - $117.21 $353,505 - $393,825
3,360 Added 2.7%
127,901 $14.4 Million
Q1 2021

Apr 28, 2021

BUY
$102.3 - $112.62 $11 Million - $12.1 Million
107,096 Added 613.91%
124,541 $13.5 Million
Q4 2020

Feb 09, 2021

SELL
$80.49 - $108.67 $8.45 Million - $11.4 Million
-105,030 Reduced 85.76%
17,445 $1.87 Million
Q3 2020

Nov 02, 2020

BUY
$85.91 - $100.83 $59,879 - $70,278
697 Added 0.57%
122,475 $10.7 Million
Q2 2020

Aug 11, 2020

BUY
$73.37 - $98.18 $1.6 Million - $2.15 Million
21,867 Added 21.89%
121,778 $12 Million
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $184,792 - $280,168
2,865 Added 2.95%
99,911 $7.61 Million
Q4 2019

Feb 13, 2020

BUY
$72.13 - $90.25 $1.91 Million - $2.39 Million
26,516 Added 37.6%
97,046 $8.59 Million
Q3 2019

Oct 17, 2019

BUY
$62.98 - $75.72 $660,282 - $793,848
10,484 Added 17.46%
70,530 $5.34 Million
Q2 2019

Aug 05, 2019

BUY
$65.7 - $83.98 $798,517 - $1.02 Million
12,154 Added 25.38%
60,046 $4.37 Million
Q1 2019

Apr 16, 2019

BUY
$77.14 - $90.79 $367,109 - $432,069
4,759 Added 11.03%
47,892 $3.86 Million
Q4 2018

Jan 17, 2019

SELL
$77.85 - $96.01 $494,970 - $610,431
-6,358 Reduced 12.85%
43,133 $3.98 Million
Q3 2018

Nov 02, 2018

SELL
$88.91 - $98.84 $1.67 Million - $1.86 Million
-18,808 Reduced 27.54%
49,491 $0
Q2 2018

Jul 24, 2018

BUY
$89.78 - $106.23 $1.21 Million - $1.44 Million
13,519 Added 24.68%
68,299 $0
Q1 2018

May 03, 2018

SELL
$92.01 - $123.21 $321,206 - $430,126
-3,491 Reduced 5.99%
54,780 $5.19 Million
Q4 2017

Feb 02, 2018

BUY
$89.56 - $98.21 $215,391 - $236,195
2,405 Added 4.3%
58,271 $5.64 Million
Q3 2017

Oct 20, 2017

BUY
$69.85 - $89.22 $3.9 Million - $4.98 Million
55,866
55,866 $4.97 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $303B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.